As the cost of drug development rises there is increasing need for more predictive in vitro models for drug discovery and testing. Identifying better lead compounds has the potential to improve the efficiency of drug development.
We are working in collaboration with pharmaceutical and biotech companies to co-develop application-specific drug-screening platforms that more closely mimic living human tissues than do traditional methods.
Vascularized micro-organ (VMO) platform chips
Our scientists have pioneered the development of high-throughput microfluidic devices for multiple physiologically-relevant 3D human micro-organ systems that receive nutrients and drugs through living blood vessels, just as tissues do in the body.
We will work with you to design and develop a VMO chip customized for your purpose.
We have developed a novel 3D vascularized, human, micro-organ (VMO) high-throughput microfluidic platform technology, which promises to have a profound positive impact on drug discovery by better predicting efficacy and safety of compounds in the early stage of drug development.
We expect that application of our unique 4Design platform technology will reduce late stage drug attrition and result in huge drug discovery cost savings.
Kino Biosciences, Incorporated has not received any reviews.
Kino Biosciences, Incorporated has not received any endorsements.